Vercirnon Uses, Dosage, Side Effects and more
Vercirnon is a novel, orally active anti-inflammatory agent that targets a chemokine receptor protein implicated in both Crohn's disease and ulcerative colitis, the two principal forms of IBD. It is under investigation in clinical trial NCT01611805 (Japanese Phase I of GSK1605786).
| Attribute | Details |
|---|---|
| Trade Name | Vercirnon |
| Generic | Vercirnon |
| Vercirnon Other Names | Vercirnon |
| Type | |
| Formula | C22H21ClN2O4S |
| Weight | Average: 444.93 Monoisotopic: 444.091056 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
How Vercirnon works
Vercirnon, a small molecule, orally-available drug, is intended to control the inappropriate immune system response underlying IBD by blocking the activity of the CCR9 chemokine receptor. In adults, CCR9 is a highly specific receptor expressed by T cells that migrate selectively to the digestive tract. The trafficking of T cells to the small and large intestine causes persistent inflammation that may result in Crohn's disease or ulcerative colitis - the two principal forms of IBD.
